Proactive Investors - Run By Investors For Investors

GlaxoSmithKline asset swap done; now for the £4bn handback

GlaxoSmithKline asset swap done; now for the £4bn handback

Shares in GlaxoSmithKline (LON:GSK) tracked the market higher after it completed £13bn of asset swaps with Novartis that will unlock a £4bn windfall for investors.

The three-stage deal will see GSK form a consumer health joint-venture with its partner, while buying its vaccines business. At the same time Novartis is acquiring Glaxo’s cancer drugs portfolio.

GSK will receive just over £5bn, which will allow it to make the pay-out.

At the moment, the British firm expects to return the cash via the issue of new B shares in the business that will then be bought back.

It has taken almost a year to get the transaction to completion.

GSK will announce first quarter results on May 6 at which point it will provide guidance on 2015 earnings, which so far been delayed.

Share in the company, down around 7.5% in the last year, rose 6.82p to 1,548.32p in early trade.

View full GSK profile View Profile

GlaxoSmithKline PLC Timeline

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use